RATIONALE: Our previous study has demonstrated that lung transplant (LT) recipients with severe hypogammaglobulinemia (HGG) are at increased risk for recurrent pneumonias and more antibiotic courses at 1-year post-transplant. The significance of IgG subclass deficiency has not yet been examined in the LT population. METHODS: IgG subclass levels were measured before LT in a singlecenter prospective observational study and related to 1-year post-transplant infectious outcomes and survival. Analysis was performed using nonparametric tests. RESULTS: 116 LT recipients were evaluated. The median age at transplant was 56.8 years, 62.2% of subjects were males, and 91.8% were Caucasian. 35% of subjects had idiopathic pulmonary fibrosis (IPF) and 32% had chronic obstructive pulmonary disease (COPD). Low IgG2 subclass level was associated with low pre-transplant pneumococcal titers (p 5 0.005) as well as an increased incidence of pneumonias (p 5 0.001) and decreased survival (p50.014). The total number of pneumonias, two or more pneumonias, and the number of days with pneumonia were also related to low IgG2 level (p 5 0.0008 for all values). Low IgG2 subclass level was associated with a higher number of post-transplant hospital days (p 5 0.01) and ICU days (p 5 0.052). IgG subclass levels were not related to the type of induction agent, post-transplant immunosuppression regimen or lymphocyte levels. CONCLUSIONS: Low pre-transplant IgG2 subclass level may represent an important novel immunologic biomarker in lung transplantation due to its association with increased pneumonias and decreased survival at 1-year post-transplant. The mechanism of these findings will need be studied further. [0, 16.65] events/patient year). CONCLUSIONS: At similar IgG doses (g/kg bw), serum IgG trough levels in obese and non-obese PID patients are close, and we found no evidence of relevant difference in efficacy. Therefore, individualized dosing within the same ranges may be considered for both obese and non-obese patients.
) PID patients were eligible for analysis. The median (range) age of obese and non-obese patients was 53.5 (13-64.0) and 20.5 (3-81) years, respectively; the majority had CVID (100% and 69.4%). The IVIG infusion schedules were similar in both groups (4-week schedule: 70.0% vs 76.1%), as were median (range) , also manufactured by Grifols, but it has twice the immune globulin concentration (20%) compared to Gamunex-C (10%). With over 15 years of clinical experience, Gamunex-C has an extensive record of safety and tolerability when administered intravenously and subcutaneously in diverse patient populations. METHODS: A number of batches of IGSC 20% have been produced at full industrial scale in order to support clinical studies and process validation. A comprehensive panel of testing has been applied to characterize these batches, including tests for purity, composition and neutralizing activity. Results are presented as average 6 standard deviation. RESULTS: Test results show IGSC 20% consists of 100% gamma globulin by electrophoresis, and is present primarily as monomer plus dimer IgG (9961%) with minimal aggregate or fragment. IgG subclass distribution are at levels of 6262% (IgG1), 3061% (IgG2), 4.360.1% (IgG3) and 3.260.2% (IgG4). Results of specific antibody testing show the presence of neutralizing antibodies to Diphtheria toxin (14.064.9 AU/ mL), Measles Virus (1.3660.26 x US Reference) and Polio Virus Type 1 (0.93 60.18 x US Reference). CONCLUSIONS: IGSC 20% shows characteristics comparable to Gamunex Ò -C, but with twice the IgG concentration to facilitate subcutaneous administration with reduced volumes. It has a subclass distribution similar to normal plasma, and demonstrated neutralizing activity for a number of specific antigens.
